Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acrivon Therapeutics, Inc.ACRV · Entity 573 | Director | June 17, 2026 | June 22, 2026 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Chief Scientific Officer | March 29, 2022 | March 31, 2022 |
| Nasus Pharma LtdNSRX · Entity 7254 | Director | March 18, 2026 | March 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acrivon Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.52 · Expires 2036-06-16 | Direct | 20,275 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 20,275 · Balance 20,275 F1: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.
Karyopharm Therapeutics Inc.
Report date March 29, 2022 · Filed March 31, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 958,131 |
Reported balance
After 2022-03-29 transaction · row 1
1 source rowRow 1 · 2022-03-29 · Grant · Acquired 60,000 · Balance 958,131 F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.33 · Expires 2032-03-28 | Direct | 90,000 |
Reported balance
After 2022-03-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-29 · Grant · Acquired 90,000 · Balance 90,000 F2: This option was granted on March 29, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 713,757 |
Reported balance
Holding disclosure · report date 2022-03-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 713,757 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.
F2: This option was granted on March 29, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Nasus Pharma Ltd
Report date March 18, 2026 · Filed March 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.38 · Expires 2035-12-11 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Options to purchase 10,000 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on December 11, 2025, with 2.0833% of the total grant vesting monthly following December 11, 2025. As of March 18, 2026, 10,000 options remain outstanding, of which 625 are vested and exercisable, at an exercise price of $5.38 per share, expiring December 11, 2035. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase 10,000 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on December 11, 2025, with 2.0833% of the total grant vesting monthly following December 11, 2025. As of March 18, 2026, 10,000 options remain outstanding, of which 625 are vested and exercisable, at an exercise price of $5.38 per share, expiring December 11, 2035.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2018 Filed May 8, 2018 20:19 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-18-028569 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,697 Underlying: Common Stock · 10,000 shares Expires 2021-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 14, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| May 07, 2018 Filed May 8, 2018 20:19 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $16.77 | $167,747.00 |
DisclosureSEC source: 0001209191-18-028569 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713,510 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.45 to $17.02, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 07, 2018 Filed May 8, 2018 20:19 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $0.26 | $2,640.00 |
DisclosureSEC source: 0001209191-18-028569 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 20:07 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 7,576 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-18-025694 · doc4.xml · derivative · entry 7 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 18,181 Underlying: Common Stock · 7,576 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F6 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on June 18, 2013, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 20:07 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 2,424 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-18-025694 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 2,424 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 12, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 20:07 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $14.79 | $147,878.00 |
DisclosureSEC source: 0001209191-18-025694 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 512,143 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $14.665 to $15.09, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 20:07 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $0.26 | $2,640.00 |
DisclosureSEC source: 0001209191-18-025694 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 522,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| April 09, 2018 Filed Apr 10, 2018 20:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-18-024504 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,697 Underlying: Common Stock · 10,000 shares Expires 2021-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 14, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| April 09, 2018 Filed Apr 10, 2018 20:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $12.48 | $124,829.00 |
DisclosureSEC source: 0001209191-18-024504 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713,510 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.20 to $12.64, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 09, 2018 Filed Apr 10, 2018 20:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $0.26 | $2,640.00 |
DisclosureSEC source: 0001209191-18-024504 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 20:36 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-18-020884 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,424 Underlying: Common Stock · 10,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 12, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 20:36 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $15.29 | $152,895.00 |
DisclosureSEC source: 0001209191-18-020884 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 512,143 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $14.90 to $15.89, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 20:36 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $0.26 | $2,640.00 |
DisclosureSEC source: 0001209191-18-020884 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 522,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| March 07, 2018 Filed Mar 8, 2018 22:54 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 606 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-18-018197 · doc4.xml · derivative · entry 7 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,697 Underlying: Common Stock · 606 shares Expires 2021-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 14, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| March 07, 2018 Filed Mar 8, 2018 22:54 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 9,394 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-18-018197 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,394 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 12, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| March 07, 2018 Filed Mar 8, 2018 22:54 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $16.15 | $161,463.00 |
DisclosureSEC source: 0001209191-18-018197 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713,510 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.89 to $16.41, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 07, 2018 Filed Mar 8, 2018 22:54 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $0.26 | $2,640.00 |
DisclosureSEC source: 0001209191-18-018197 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-18-012382 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,424 Underlying: Common Stock · 10,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 12, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $14.79 | $147,872.00 |
DisclosureSEC source: 0001209191-18-012382 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 512,143 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $14.51 to $15.015, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $0.26 | $2,640.00 |
DisclosureSEC source: 0001209191-18-012382 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 522,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| February 07, 2018 Filed Feb 8, 2018 21:07 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-18-008415 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,394 Underlying: Common Stock · 10,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 12, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| February 07, 2018 Filed Feb 8, 2018 21:07 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $12.50 | $125,048.00 |
DisclosureSEC source: 0001209191-18-008415 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713,510 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.40 to $12.67, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 07, 2018 Filed Feb 8, 2018 21:07 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $0.26 | $2,640.00 |
DisclosureSEC source: 0001209191-18-008415 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 21:28 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001209191-18-005379 · doc4.xml · derivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: This option was granted on January 24, 2018. The shares underlying this option vest as to 25% of the shares on January 24, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 21:28 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001209191-18-005379 · doc4.xml · derivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: This option was granted on January 24, 2018. The shares underlying this option vest as to 25% of the shares on January 24, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 18, 2018 Filed Jan 22, 2018 21:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-18-004725 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 22,424 Underlying: Common Stock · 10,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 12, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| January 18, 2018 Filed Jan 22, 2018 21:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $10.09 | $100,882.00 |
DisclosureSEC source: 0001209191-18-004725 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 512,143 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.90 to $10.15, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 18, 2018 Filed Jan 22, 2018 21:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $0.26 | $2,640.00 |
DisclosureSEC source: 0001209191-18-004725 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 522,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| January 08, 2018 Filed Jan 9, 2018 21:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-18-002907 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,394 Underlying: Common Stock · 10,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 12, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| January 08, 2018 Filed Jan 9, 2018 21:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $10.08 | $100,769.00 |
DisclosureSEC source: 0001209191-18-002907 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713,510 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.96 to $10.29, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 08, 2018 Filed Jan 9, 2018 21:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $0.26 | $2,640.00 |
DisclosureSEC source: 0001209191-18-002907 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-17-066639 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 32,424 Underlying: Common Stock · 10,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F5 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 12, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $9.16 | $91,553.00 |
DisclosureSEC source: 0001209191-17-066639 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 512,143 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.0501 to $9.3500, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $0.26 | $2,640.00 |
DisclosureSEC source: 0001209191-17-066639 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 522,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 21:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001209191-17-064683 · doc4.xml · derivative · entry 6 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,394 Underlying: Common Stock · 10,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 12, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter. Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 21:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 10,000 | $10.39 | $103,903.00 |
DisclosureSEC source: 0001209191-17-064683 · doc4.xml · nonDerivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713,510 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.14 to $10.48, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 21:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 10,000 | $0.26 | $2,640.00 |
DisclosureSEC source: 0001209191-17-064683 · doc4.xml · nonDerivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Reflects the contribution of 60,000 shares previously owned directly to the Sharon Shacham 2016 Qualified Annuity Interest Trust ("GRAT") on September 9, 2016 and the transfer of 12,691 shares from the GRAT to the reporting person on November 6, 2017. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 22:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001209191-17-005323 · doc4.xml · derivative · entry 2 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-01-19 F1 · derivative.exercise_date: This option was granted on January 20, 2017. The shares underlying this option vest as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 22:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001209191-17-005323 · doc4.xml · derivative · entry 1 Shacham Sharon · CIK 0001588438 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-01-19 F1 · derivative.exercise_date: This option was granted on January 20, 2017. The shares underlying this option vest as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.